Hubei Biocause Pharmaceutical
Hubei Biocause Pharmaceutical Co., Ltd. primarily provides life and motor insurance products in China. It also engages in the pharmaceutical, chemical, and new energy fuel businesses. In addition, the company is involved in the contract research and production of APIs, intermediates, and formulations, including tablets, granules, capsules, etc.; and provision of chemicals comprising dimethyl ethe… Read more
Hubei Biocause Pharmaceutical (000627) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2023: 0.008x
Based on the latest financial reports, Hubei Biocause Pharmaceutical (000627) has a cash flow conversion efficiency ratio of 0.008x as of September 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥276.06 Million) by net assets (CN¥33.70 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Hubei Biocause Pharmaceutical - Cash Flow Conversion Efficiency Trend (2001–2023)
This chart illustrates how Hubei Biocause Pharmaceutical's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Hubei Biocause Pharmaceutical Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hubei Biocause Pharmaceutical ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Palm Landscape Architecture Co Ltd
SHE:002431
|
0.097x |
|
Jahwa Electron
KO:033240
|
0.032x |
|
Nexus Real Estate Investment Trust
PINK:EFRTF
|
0.005x |
|
Nanjing Doron Technology Corp
SHG:603528
|
0.003x |
|
Jiangxi Salt Industry Group Co. Ltd. A
SHG:601065
|
N/A |
|
Samkang M&T Co.Ltd
KQ:100090
|
0.132x |
|
Hirose Electric Co.Ltd
PINK:HROEY
|
0.028x |
|
Creades AB
ST:CRED-A
|
0.000x |
Annual Cash Flow Conversion Efficiency for Hubei Biocause Pharmaceutical (2001–2023)
The table below shows the annual cash flow conversion efficiency of Hubei Biocause Pharmaceutical from 2001 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | CN¥33.63 Billion | CN¥9.53 Billion | 0.283x | +30.37% |
| 2022-12-31 | CN¥34.60 Billion | CN¥7.52 Billion | 0.217x | +95.29% |
| 2021-12-31 | CN¥37.47 Billion | CN¥4.17 Billion | 0.111x | -82.02% |
| 2020-12-31 | CN¥34.59 Billion | CN¥21.42 Billion | 0.619x | -25.61% |
| 2019-12-31 | CN¥34.35 Billion | CN¥28.60 Billion | 0.833x | +44.56% |
| 2018-12-31 | CN¥26.01 Billion | CN¥14.98 Billion | 0.576x | +3463.41% |
| 2017-12-31 | CN¥26.70 Billion | CN¥431.58 Million | 0.016x | +114.07% |
| 2016-12-31 | CN¥20.40 Billion | CN¥-2.34 Billion | -0.115x | -338.31% |
| 2015-12-31 | CN¥1.78 Billion | CN¥-46.73 Million | -0.026x | -128.83% |
| 2013-12-31 | CN¥1.44 Billion | CN¥130.53 Million | 0.091x | +48.97% |
| 2012-12-31 | CN¥1.54 Billion | CN¥93.79 Million | 0.061x | +28.87% |
| 2011-12-31 | CN¥1.41 Billion | CN¥66.95 Million | 0.047x | -66.23% |
| 2010-12-31 | CN¥1.60 Billion | CN¥224.58 Million | 0.140x | +2.40% |
| 2007-12-31 | CN¥866.03 Million | CN¥118.56 Million | 0.137x | -22.71% |
| 2006-12-31 | CN¥723.71 Million | CN¥128.19 Million | 0.177x | +166.20% |
| 2005-12-31 | CN¥731.23 Million | CN¥48.66 Million | 0.067x | -14.08% |
| 2004-12-31 | CN¥723.91 Million | CN¥56.07 Million | 0.077x | +58.41% |
| 2001-12-31 | CN¥762.99 Million | CN¥37.30 Million | 0.049x | -- |